Alirocumab reduces dangerous coronary plaque and stabilizes high-risk lesions

Intensive LDL-C lowering with alirocumab significantly reduces high-risk coronary plaque burden, transforming unstable plaques into more stable phenotypes. This lesion-level analysis underscores the enhanced efficacy compared to vessel-level approaches.

Challenging the chronic brain disease model of addiction

Addiction is not simply a chronic brain disease and considering it as such can limit treatment options and increase stigma, an extensive research review suggests.

July 1, 2024

Machine learning unlocks personalized approach to early ovarian cancer detection

For over three decades, a highly accurate early diagnostic test for ovarian cancer has eluded physicians.

January 30, 2024

RNS-60 by Revalesio for Acute Ischemic Stroke: Likelihood of Approval

RNS-60 is under clinical development by Revalesio and currently in Phase II for Acute Ischemic Stroke.

June 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.